Stockwatch: Fifty shades of fail
This article was originally published in Scrip
Executive Summary
While stock market analysts ponder the reasons for the current low volatility of broad market stock indices like the S&P500 and rising stock prices, against the backdrop of what the bond market suggests will be a partial dissolution of the Euro, investors in some biotechnology stocks do not seem to be asking any questions before parting with their money.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.